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Abstract
Background: Teriflunomide, an inhibitor of dihydroorotate dehydrogenase, is thought to ameliorate multiple
sclerosis by reducing activation-induced proliferation of lymphocytes, which is highly dependent on de novo
pyrimidine synthesis. Nevertheless, its immunomodulatory effects on resident glial cells in the central nervous
system are only poorly understood.
Methods: In this study, we employed physiologically relevant concentrations of teriflunomide and investigated its
effects on survival, proliferation, activation, and function of primary rat microglia in vitro.
Results: We demonstrate that teriflunomide had no cytotoxic effect on microglia and had only a minor impact on
microglial activation. In a concentration- and time-dependent manner, teriflunomide significantly downregulated
surface expression of the co-stimulatory molecule CD86. Furthermore, in the highest concentration applied (5 μM),
it slightly increased the expression of interleukin-10 in microglia in response to lipopolysaccharide. Treatment with
low concentrations of teriflunomide (0.25–1 μM) did not have any impact on the activation or proliferation of
microglia. At 5 μM concentration of teriflunomide, we observed a reduction of approximately 30 % in proliferation
of microglia in mixed glial cell cultures.
Conclusions: Taken together, our in vitro findings suggest that at higher concentrations, teriflunomide potentially
exerts its effects by reducing microglial proliferation and not by modulating the M1-/M2-like cell differentiation of
primary rat microglia. Thus, teriflunomide has no major impact on the plasticity of microglia; however, the anti-
proliferative and minimal anti-inflammatory effects might be clinically relevant for immune modulation in the
treatment of neuroinflammatory CNS diseases such as multiple sclerosis.
Keywords: Multiple sclerosis, Teriflunomide, Microglia, Proliferation, Pro-inflammatory (M1),
Anti-inflammatory (M2)
Background
Teriflunomide is an immunomodulatory disease-modifying
therapy (DMT) for relapsing-remitting multiple sclerosis
(RRMS). It is thought to act primarily via a specific, non-
competitive, and reversible inhibition of the activity of
the mitochondrial enzyme dihydroorotate dehydrogenase
(DHODH), which is required for de novo pyrimidine syn-
thesis of rapidly dividing cells such as activated lympho-
cytes [1, 2]. Resting lymphocytes synthesize the nucleotide
pyrimidine through the DHODH-independent salvage
pathway and therefore are largely unaffected by terifluno-
mide [3]. Teriflunomide is the active metabolite of lefluno-
mide in vivo which is an effective agent in the treatment
of rheumatoid arthritis (RA) [4].
Several studies indicate that teriflunomide rather ex-
erts cytostatic and not cytotoxic effects on actively
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proliferating lymphocytes in the periphery [5, 6]. This
limits the availability of autoreactive T and B cells that
can infiltrate into the central nervous system (CNS) in
CNS inflammatory diseases such as multiple sclerosis
(MS) [7]. Other effects of teriflunomide such as the in-
hibition of adhesion molecules, cytokines, protein tyro-
sine kinases, nuclear factor-kB (NF-kB) activation, and
cyclooxygenase 2 activity have also been demonstrated
in some in vitro studies, suggesting that teriflunomide
in addition to its anti-proliferative effects may also
impact signal transduction, migration, and inflamma-
tory processes [8, 9].
Pharmacokinetic analysis of patients treated with teri-
flunomide revealed a concentration of 20–60 mg/l in the
serum. Owing to its low permeability through the blood-
brain barrier (BBB), only approximately 1–2 % of the
serum concentration of drug reaches the CNS, which
is approximate to a concentration of 1–3 μM in vivo
[10, 11]. Thus, CNS resident cells like microglia are
exposed to much lower concentrations of teriflunomide
than the immune cells in the periphery. However, these
concentrations are still in the range where, e.g., the
DHODH is inhibited and thus therapeutic concentrations
of teriflunomide may modulate microglia. Microglia are
considered to play key regulatory and effector functions
during the onset and progression of CNS diseases [12].
Microglial activation in the CNS during neuroinflamma-
tion can have both beneficial and detrimental effects. By
virtue of their phagocytic ability, they assist in clearing
debris which in turn might hasten the repair processes
[13]. Furthermore, several inflammatory factors produced
by activated microglia are essential for repair processes
[14]. On the other hand, activated microglia serve as
antigen-presenting cells and are involved in the reactiva-
tion of the CNS-infiltrating autoreactive T lymphocytes
and thereby promoting neural tissue damage. Additionally,
neuroinflammation triggers the release of toxic reactive
oxygen species such as nitric oxide by microglia, which is
highly toxic to neurons.
In order to explore the potential of teriflunomide to
modulate microglia, we applied physiologically relevant
concentration of 0.25–5 μM on primary rat microglia
and investigated various functions.
Methods
Mixed glial cell cultures
Primary microglia from neonatal Sprague-Dawley rats
(Crl:CD) were isolated by the method of Giulian and
Baker [15] as previously described [16]. Briefly, brains
were freed from meninges and dissociated mechanically
and enzymatically with 0.1 % trypsin (Biochrom, Merck
Millipore, Darmstadt, Germany) and 0.25 % DNase (Roche
Diagnostic GmbH, Mannheim, Germany). Cells were
plated at 1–2 brains per poly-L-lysine (Sigma-Aldrich,
Munich, Germany) coated culture flasks (25 cm2; 75 cm2;
Sarstedt, Nümbrecht, Germany) and cultivated in
Dulbecco’s Modified Eagle Medium (DMEM; life
technologies, Carlsbad, USA) supplemented with 10 %
fetal calf serum (FCS; Biochrom, Merck Millipore,
Darmstadt, Germany) and 1 % penicillin/streptomycin
(life technologies, Carlsbad, USA; culture medium referred
to as: MGP+), where indicated culture flasks were treated
with granulocyte macrophage-colony stimulating factor
(GM-CSF; 5 ng/ml; Peprotech; Hamburg, Germany). After
7–8 days, loosely attached microglia were harvested from
mixed glial cell cultures by shaking for 30–45 min on an
orbital shaker-incubator (Edmund Bühler, Hechingen,
Germany) at 37 °C. Cells in the supernatant were re-
plated at 3–6 × 104 cells per 12-mm glass coverslip in
24-well plates for immunocytochemistry staining, dir-
ectly resuspended in 500 μl MGP+ for BrdU flow cy-
tometry, 5 × 105 per well in 6-well plates for reverse
transcription polymerase chain reaction (RT-PCR), or
2.5 × 105 in 12-well plates (all Nunc, Life Technologies,
Paisley, UK) for phagocytosis and flow cytometry analysis.
The remaining astrocytes were washed with PBS and har-
vested with 0.25 % trypsin/0.05 % EDTA. After isolation,
the astrocytes were incubated with an APC-conjugated
mouse/rat anti-GLAST (ACSA-1) antibody and with
FITC-conjugated anti-BrdU antibody.
Microglia were incubated overnight at 37 °C, 5 % CO2,
and the following day, cells were treated with 0, 0.25,
0.5, 1, and 5 μM of teriflunomide (stock: 10 mM,
dissolved in dimethyl sulfoxide (DMSO); Genzyme,
Waltham, MA; USA) with or without indicated stimuli
for the designated period of time for each experiment.
Cell culture purity and cell viability were analyzed by
immunofluorescence stainings with CD11b/c or Iba-1,
markers for microglia/macrophages, and DAPI or PI,
markers for cell viability. Results were quantified by flow
cytometry or fluorescence microscopy.
BrdU flow cytometry analysis of primary mixed glial cell
cultures
The incorporation of 5-bromo-2′-deoxyuridine (BrdU)
was analyzed in mixed glial cell cultures using flow cy-
tometry and labeling with a conjugate anti-BrdU anti-
body (FITC BrdU flow kit, BD Pharmingen, CA, USA).
Mixed glial cell cultures were incubated with 0.25–5 μM
teriflunomide and co-treated with GM-CSF (5 ng/ml;
Peprotech, Hamburg, Germany) from day 5 after prepar-
ation. The next day, 10 μM BrdU (FITC BrdU flow kit,
BD Pharmingen) was added for 16 h.
After microglia isolation, the Fc receptors were
blocked with mouse anti-rat CD32 for 30 min on ice
(clone: D34-485; BD Pharmingen). Surface staining of
microglia was done with allophycocyanin (APC)-conju-
gated rat anti-CD11b/c antibody for 30 min at 4 °C.
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Cells were then fixed and permeabilized with fixation/
permeabilization buffer (Foxp3 Staining Buffer Set;
eBioscience) according to the manufacturer’s instruc-
tions. The samples were treated with DNase to expose
incorporated BrdU (diluted to 300 μg/ml; BrdU flow kit,
BD Pharmingen) for 1 h at 37 °C and finally stained with
fluorescein isothiocyanate (FITC)-conjugated anti-BrdU
antibody (30 min at RT, 1:100; BrdU flow kit, BD Phar-
mingen). The analysis was carried out using a FACSCali-
bur with CellQuest software (BD). Measurements were
performed in duplicates per condition and in four inde-
pendent experiments.
T cell proliferation assay
Single-cell suspensions from spleens of adult Sprague-
Dawley rats (Crl:CD) were prepared in complete Iscove’s
Modified Dulbecco’s Medium (IMDM) medium. After
passage through a 100-μm-mesh-size cell strainer (BD
Falcon), red blood cells were lysed by NH4Cl treatment.
CD4+ T cells were purified by MACS technology using
MagCellect rat CD4+ T Cell Isolation Kit (R&D Systems,
Minneapolis, USA) according to the manufacturer’s
instructions. The final depleted cell fraction contained
the desired highly enriched CD4+ T cells. Purity of the
enriched CD4+ T cells was analyzed with a phycoeryth-
rin (PE)-conjugated anti-rat CD4 antibody (W3/25) and
a FITC-conjugated anti-rat T cell receptor α/β antibody
(R73). Enriched CD4+ T cells were labeled with 2.5 μM
carboxyfluorescein succinimidyl ester (CFSE; Invitrogen,
Darmstadt, Germany), respectively, for 10 min at 37 °C.
Labeling of cells was stopped by the addition of ice-cold
complete IMDM medium and by three washing steps.
CFSE-labeled and unlabeled CD4+ Rat T cells (1 × 105
cells/well) were seeded in 96-well microtiter plates
(Nunc™ 96-Well Polystyrene Round Bottom Microwell
Plates, Thermo Fisher Scientific, USA) in 100 μl medium
with the addition of different concentrations of teriflu-
nomide and stimulated with 3 μg/ml of plate-bound
anti-CD3 mAb/anti-CD28 mAb. The final culture volume
was adjusted to 200 μl per well. Cells were maintained at
37 °C in a humidified atmosphere with 5 % CO2. After
65–72 h incubation, cells were washed in PBS, collected
and the absolute amount of proliferating rat T cells was
determined by flow cytometry.
RNA isolation and reverse transcription polymerase chain
reaction
To determine the messenger RNA (mRNA) levels of
pro-inflammatory factors such as iNOS, TNF-α, and IL-
1β, anti-inflammatory factors such as Arg1 and IL-10,
and growth factor IGF-1, or mRNA level of DHODH,
real-time PCR analysis was performed (Table 1).
For cytokine analysis, total RNA was isolated from
microglia pre-treated with different concentrations of
teriflunomide (0.25–5 μM) for 12 h and cultured for an
additional 12 h with different supplements: (1) recombin-
ant rat interferon (IFN)-γ (50 ng/ml; Peprotech, Hamburg,
Germany) plus lipopolysaccharide (LPS; 100 ng/ml;
Sigma-Aldrich, Munich, Germany) and (2) recombinant
rat IL-4 (20 ng/ml; Peprotech, Hamburg, Germany) to in-
duce a M1- and M2-like phenotype, respectively.
For DHODH expression analysis, we used two experi-
mental designs. Firstly, we isolated total RNA from
microglia pre-treated with different concentrations of
teriflunomide (0.25–5 μM) for 12 h and cultured for an
additional 12 h with medium containing IFN-γ (50 ng/ml;
Peprotech, Hamburg, Germany) plus LPS (100 ng/ml;
Sigma-Aldrich, Munich, Germany) or MGP+ medium.
Secondly, we isolated total RNA from microglia from
mixed glial cell cultures co-treated with different con-
centrations of teriflunomide (0.25–5 μM) and 5 ng/ml
GM-CSF or medium for 12 h.
The RNeasy®Micro Kit (Qiagen, Hilden, Germany) was
used according to the manufacturer’s instructions. The
RNA concentration was measured using a NanoDrop
2000 spectrophotometer (Thermo Fisher Scientific, MA,
USA). Complementary deoxyribonucleic acid (cDNA)
was synthesized using the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). qPCR analysis was performed using
the StepOne™ Real-Time PCR System and appropriate
TaqMan assay (Applied Biosystems; see Table 1). The
experiments were performed with cDNA from 400 ng
total RNA, and all primers were exon-spanning. The
ΔΔCT method was used to determine differences in
the expression between controls and drug-treated
microglia exposed to M1/M2 or GM-CSF stimuli.
Changes in the mRNA expression levels were quanti-
fied against the housekeeping gene hypoxanthine-
guanine phosphoribosyl-transferase (HPRT) 1 compared
with control.
Table 1 Primer used for polymerase chain reaction









DHODH dihydroorotate dehydrogenase, IL-1β interleukin-1beta, IL-10
interleukin-10, iNOS inducible nitric oxide synthase, Arg1 arginase1, TNF-α
tumor necrosis factor-alpha, IGF-1 insulin-like growth factor-1, HPRT
hypoxanthine-guanine phosphoribosyl-transferase
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Flow cytometry
LPS (100 ng/ml; Sigma-Aldrich, Munich, Germany)
stimulated microglia were cultured in the absence or
presence of teriflunomide (0.25–5 μM) for 48 or 72 h.
After incubation, cells were washed and harvested by
0.05 % trypsin/EDTA treatment and collected in poly-
styrene tubes. After centrifugation (352×g, 10 min), cells
were resuspended in 100 μl of PBS and subsequently
incubated with the fluorescent-labeled antibodies for
30 min on ice: APC-conjugated anti-rat CD11b/c mAb
(OX-42, 1:100), PE-conjugated anti-rat CD86 mAb (24 F,
1:100), or appropriate isotype control for anti-rat CD86
(mouse IgG1, k, 1:100) (all from BioLegend, California,
USA).
After incubation, cells were washed, pelleted by centri-
fugation (352×g, 10 min), and resuspended in 250 μl of
PBS. Cells were immediately analyzed with FACSCalibur
(Becton-Dickinson, San Jose, CA, USA) and CellQuest
software (BD Biosciences). Dead cells were excluded by
propidium iodide staining.
Western blot analysis
For Western blot analysis, microglia were treated with
or without 5 μM teriflunomide for 12 h and then stimu-
lated additionally with LPS/IFN-γ (100 ng/ml; Sigma-
Aldrich, Munich, Germany; 50 ng/ml; Peprotech, Ham-
burg, Germany) for 0, 15, 30, or 60 min at 37 °C. Cells
were washed with cold PBS and lysed in RIPA buffer
supplemented with 1 % protease and phosphatase inhibi-
tor (Cell Signaling Technology; Roche). The protein con-
tent was measured using a Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific). The lysate (30 μg of protein)
was mixed with Laemmli buffer and boiled for 5 min at
95 °C. After the NF-kB activation reaction, Western blot
analysis was performed as described [17] using anti-total
IkBα (1:1000, rabbit, Cell Signaling Technology) and β-
actin (1:3000, mouse, Santa Cruz Biotechnology) followed
by horseradish peroxidase (HRP)-coupled goat anti-mouse
or goat anti-rabbit secondary antibodies (Santa Cruz
Biotechnology).
Proteins were visualized by enhanced chemilumines-
cence (ECL, Pierce Biotechnology, Illinois, USA; Millipore,
Massachusetts, USA) after treatment with the secondary
antibody using the ChemoCam system (Intas, Science
Imaging Instruments GmbH, Göttingen, Germany) accord-
ing to the manufacturer’s instructions. Quantification of
protein levels by densitometry was conducted on acquired
images using LabImage 1D software (Kapelan Bio-Imaging
Solutions, Leipzig, Germany).
Phagocytosis assay
Phagocytic activity of microglia was determined by
measuring the uptake of fluorescent latex beads on flow
cytometry as previously described [18]. After 24 h
teriflunomide (±12 h LPS; 100 ng/ml; Sigma-Aldrich,
Munich, Germany) treatment, FITC-labeled latex beads
(1 μm, Fluoresbrite™ Yellow Green carboxylate micro-
spheres; Polysciences, Warrington, USA) were added at
a cell:bead ratio of 1:100 and incubated for 1 h at 37 °C.
In parallel, cells incubated with beads on ice (4 °C)
served as negative controls. Non-phagocytosed and sur-
face bound beads were removed by washing six times
with ice-cold PBS. Adherent microglia were then har-
vested by 0.05 % trypsin/EDTA treatment, and the up-
take of the beads was determined by flow cytometry
(FACSCalibur; Becton-Dickinson, San Jose, CA, USA).
Dead cells were excluded by propidium iodide staining.
A shift in mean fluorescence intensity (MFI) resulting
from the uptake of fluorescent beads and the percentage
of gated microglia that phagocytosed latex beads were
used as a measure to assess phagocytosis. Active phago-
cytosis was then calculated by subtracting measured
values of cells incubated at 4 °C from the values ob-
tained at 37 °C.
Statistical analysis
All experiments were performed at least four times, and
arithmetic means ± standard deviation (SD) was calcu-
lated using GraphPad Prism 5.0 software. Comparison of
two samples was performed using a one-sample t test or
a paired Student’s t test followed by the correction for
multiple comparisons by Benjamini and Hochberg [19].
Multiple samples were evaluated using repeated mea-
sures ANOVA with Bonferroni’s multiple comparison t
tests. P values <0.05 were considered statistically signifi-
cant (*p < 0.05, **p < 0.01, ***p < 0.001).
Results
Regulation of DHODH-mRNA expression in microglia
Previous reports have revealed that teriflunomide in-
hibits activation-induced proliferation of T cells by tar-
geting DHODH, which is a crucial enzyme involved in
de novo synthesis of pyrimidine nucleotides [1, 2].
Therefore, we initially assessed if DHODH is induced in
microglia upon activation. Following the stimulation of
microglia with LPS/IFN-γ or GM-CSF, we studied the
expression of DHODH-mRNA by RT-PCR. Compared
to medium-treated control, we observed a significant
upregulation of DHODH in LPS/IFN-γ (Fig. 1a) and
GM-CSF-treated microglia (Fig. 1b). Furthermore, we
observed that pre-treatment of microglia with terifluno-
mide prior to activation per se did not influence the
mRNA expression, confirming that teriflunomide inhib-
ition of DHODH might be at the protein level and not
at the gene expression level. The slight decrease of
DHODH-mRNA of approximately 20 % in GM-CSF-
treated microglia by 5 μM teriflunomide was not bio-
logically significant (Fig. 1b).
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Teriflunomide does not interfere with morphological
shaping of microglia
Morphological rearrangement is a major feature during
the transition of different functional stages of microglia.
Thus, we investigated if teriflunomide affects the shaping
of non-activated and activated microglia. After resting
overnight, microglia were cultured for 24 h in the pres-
ence of teriflunomide with or without LPS/IFN-γ to in-
duce activation in vitro. Using immunocytochemistry,
we observed a morphological change of their phenotype
in the presence of LPS/IFN-γ. After plating, microglia
had an amoeboid appearance that was maintained after
activation (Fig. 2). Teriflunomide treatment did not
interfere with morphological changes of microglia when
compared with non-activated and activated microglia in
control medium. Except for cell culture-associated death,
we did not observe any cytotoxic effects of teriflunomide
(Additional file 1: Figure S2, Additional file 2: Figure S3).
Teriflunomide reduces proliferation of primary microglia
It is known that teriflunomide inhibits active T cell pro-
liferation; therefore, we tested if the physiologically rele-
vant concentrations (0.25–5 μM) chosen for this study
were sufficient to inhibit T cell proliferation. For this
purpose, CFSE-labeled CD4+ T cells isolated from the
spleen of Sprague-Dawley rats were stimulated on anti-
CD3/anti-CD28 coated culture plates in the presence or
absence of different concentrations of teriflunomide
(0.25–5 μM) and CFSE dilution as an indicator of prolif-
eration was measured by flow cytometry. Even at a con-
centration as low as 0.25 μM, teriflunomide
significantly inhibited proliferation of T cells with a
concentration-dependent effect with a maximum at
5 μM (Additional file 3: Figure S1). Having confirmed
that low concentrations of teriflunomide were sufficient to
mediate anti-proliferative effects in the periphery, we next
investigated microglial proliferation.
We stimulated mixed glial cell cultures containing
astrocytes, microglia, and oligodendrocyte precursor
cells with GM-CSF in the presence or absence of teriflu-
nomide and assessed the proliferation and yield of
microglia. While the cultures were treated with GM-CSF
(5 ng/ml) and 0.25–5 μM teriflunomide on day 5, the
controls received media changes only. The prolifera-
tion was determined after day 7 as described in the
“Methods” section. We observed an increase in
microglial proliferation in mixed glial cell cultures
after treatment with 5 ng/ml GM-CSF (Fig. 3). We
also detected a slight but significant reduction by
29.7 % ± 2.3 % (mean ± SD; p = 0.0242) in the percentage
of BrdU+CD11b/c+ glial cells in GM-CSF-treated cultures
after the treatment with 5 μM teriflunomide (Fig. 3). Thus,
higher concentrations of teriflunomide may have an
anti-proliferative effect on GM-CSF-induced prolifera-
tion of microglia. We also investigated if the drug ter-
iflunomide could affect the proliferation of astrocytes
and in this way would indirectly influence the micro-
glial proliferation. As presented in Additional file 4:
Figure S4, teriflunomide did not alter astrocytic prolifera-
tion and the expression of chosen astrocyte-secreted
factors.
Teriflunomide has no impact on microglial plasticity
Similar to macrophages, microglia can be functionally
classified into either pro-inflammatory (M1-like) or anti-
inflammatory (M2-like) cells [20]. We thus investigated
the effect of teriflunomide on these functions. Primary
rat microglia were driven into either M1- or M2-like
Fig. 1 Dihydroorotate dehydrogenase (DHODH) is upregulated in activated primary microglia. Evaluation of DHODH-mRNA expression by RT-PCR
in primary rodent microglia (a) with teriflunomide pre-treatment for 12 h following 12 h stimulation with 100 ng/ml LPS/50 ng/ml IFN-γ (black
column) or medium (white column) and (b) teriflunomide co-treatment for 12 h with 5 ng/ml GM-CSF (dotted column) or medium (white column).
Data represent four biological replicates as mean ± SD. Results are presented as the fold-change normalized to the expression of the reference
gene Hprt1 and were calculated relative to unstimulated, untreated cells. Statistical analysis was performed using repeated measures ANOVA
followed by Bonferroni’s post hoc tests. P values <0.05 were considered significant. Asterisks denote a significant difference versus the indicated
control (*p < 0.05)
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Fig. 2 Teriflunomide does not modulate morphological shaping of non-activated and activated cultured microglia. Cultured microglia were
treated with teriflunomide (0.25–5 μM) for 24 h without (a–e) or with 100 ng/ml LPS/50 ng/ml IFN-γ (pre-treatment: f–j; co-treatment: k–o).
Immunofluorescence microscopy images show Iba-1+ microglia stained with DAPI as marker for cell viability (n = 4). LPS/IFN-γ-treatment (f–o)
induces morphological changes in comparison with non-activated cells (a–e). Scale bar = 20 μm
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cells by culturing them in medium containing either
LPS/IFN-γ or IL-4, respectively.
As demonstrated in Fig. 4, pro-inflammatory factors
such as iNOS, IL-1β, and TNF-α were highly upregu-
lated in microglia treated with LPS/IFN-γ and anti-
inflammatory factors such as Arg1 and IGF-1 were
significantly upregulated in IL-4-treated cells. Pre-
treatment of microglia with teriflunomide for 12 h prior
to M1- and M2-like differentiation had no effect on the
mRNA expression of any of the abovementioned pro- or
anti-inflammatory genes except for a slight but signifi-
cant increase in IL-10 expression in LPS/IFN-γ-treated
microglia pre-treated with 5 μM teriflunomide. In sum-
mary, teriflunomide had no major impact on the plasti-
city of microglia to differentiate into various phenotypes.
Teriflunomide may downregulate LPS-induced CD86
expression
Antigen-presenting properties of microglia are well
appreciated. As an efficient antigen-presenting cell,
microglia present antigens and provide the crucial co-
stimulatory signals required for the reactivation of infil-
trating autoreactive T cells. Upon activation, microglia
upregulate co-stimulatory molecules such as CD86 on
their surface and we tested if teriflunomide interfered
with this process. Following the treatment of microglia
with LPS in the presence or absence of teriflunomide
for 48 and 72 h, cell surface expression of the co-
stimulatory molecule CD86 was determined by flow
cytometry. As expected, CD86 expression was significantly
increased in LPS-treated microglia. No significant effect of
different concentrations of teriflunomide on CD86 expres-
sion was observed after 48 h treatment (Fig. 5a, c). How-
ever, the expression of CD86 was slightly but significantly
Fig. 3 Teriflunomide influences GM-CSF-mediated microglial
proliferation in vitro. Microglia were treated without (control) or with
GM-CSF (5 ng/ml) in mixed glial cell cultures for 48 h. Cultures were
incubated with 10 μM BrdU for the last 16 h, and dividing microglia
were then visualized by labeling with a FITC-conjugated anti-BrdU
antibody. For comparison of untreated (0 μM) and teriflunomide-
treated (0.25–5 μM) samples (n = 4), a paired t test was used followed
by correction for multiple comparisons by Benjamini and Hochberg.
P values <0.05 were considered significant. Asterisks denote a
significant difference versus the indicated control (*p < 0.05)
Fig. 4 Effect of teriflunomide on the expression of pro- or anti-inflammatory mediators and growth factors in primary microglia. Expression of a
pro- and b anti-inflammatory mediators in microglia with or without 12 h pre-treatment of teriflunomide (0.25–5 μM) followed by 12 h stimulation
with 100 ng/ml LPS/50 ng/ml IFN-γ (black column), 20 ng/ml IL-4 (gray column), or medium (white column). Data represent five to six biological
replicates as mean ± SD. Results were presented as the fold-change normalized to the expression of the reference gene Hprt1 and were calculated
relative to unstimulated and untreated cells. Statistical analysis was performed using repeated measures ANOVA followed by Bonferroni’s post hoc
tests. P values <0.05 were considered significant. Asterisks denote a significant difference versus the stimulated and untreated control (0 μM
teriflunomide; *p < 0.05)
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decreased on LPS-treated microglia cultured in the pres-
ence of 5 μM teriflunomide for 72 h (Fig. 5b, d).
Teriflunomide does not inhibit NF-kB activation
NF-kB is an important transcription factor which
regulates the expression of pro-inflammatory genes
and is an ideal target for immunomodulatory and
anti-inflammatory therapies. Previous studies have
shown that 5–10 μM of leflunomide completely blocked
NF-kB activation in T cells, myeloid, and epithelial
cells [21].
We therefore investigated whether teriflunomide dis-
played similar inhibitory effects on NF-kB activation
in primary microglia. NF-kB is found as a complex
with IkBα in the cytoplasm of resting cells. Upon ac-
tivation IkBα is phosphorylated and subsequently de-
graded to release NF-kB for nuclear translocation
[22–24]. Hence, we followed the kinetics of IkBα degrad-
ation, as a measure of NF-kB activation, in response to
LPS/IFN-γ in microglia pre-treated with 5 μM terifluno-
mide for 12 h.
As demonstrated in Fig. 6a, IkBα degradation was
evident within 15 min of LPS/IFN-γ-treatment. How-
ever, IkBα degradation was unaffected by terifluno-
mide treatment suggesting that teriflunomide had no
impact on this regulation in activated microglia at
the physiologically relevant concentration used here
(Fig. 6b).
Fig. 5 Teriflunomide leads to a decreased expression of CD86 in cultured microglia. Isolated microglia were treated with LPS (100 ng/ml) and
different concentrations of teriflunomide (0.25–5 μM) for 48 or 72 h. a, b The histograms represent the CD86 expression levels on the microglial
surface (filled: unstimulated cells; solid line: LPS-treated cells; dotted line: LPS-treated cells with 5 μM teriflunomide). c, d The mean fluorescence
intensities obtained were normalized to LPS-stimulated control (black column). For comparison of the untreated (0 μM) and teriflunomide-treated
samples (0.25–5 μM), a t test against the expected mean of one was used (n = 4–5). P values <0.05 were considered significant. Asterisks denote a
significant difference versus the LPS-stimulated control (*p < 0.05)
Fig. 6 No effect of teriflunomide on the NF-kB signaling pathway.
a Western blot analysis of teriflunomide pre-treated microglia
stimulated with LPS/IFN-γ (100 ng/ml; 50 ng/ml) for the indicated
times using IkBα antibody. β-actin was used as loading control.
b Summary of four independent experiments as in a normalized to
β-actin and expressed as mean ± SD. Data were analyzed by repeated
measures ANOVA with Bonferroni’s multiple comparison t test
compared to the LPS/IFN-γ control. Significant effects are indicated by
asterisks (***p < 0.001)
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Phagocytic activity of microglia is unaffected by
teriflunomide
Phagocytosis is one of the major functions of microglia.
Microglia treated with or without LPS were incubated
with different concentrations (0.25–5 μM) of terifluno-
mide for 24 h. Subsequently, the uptake of latex beads
by microglia was measured by flow cytometry. As shown
in Fig. 7, teriflunomide did not change the phagocytic
activity of both untreated and LPS-treated microglia.
Discussion
In 2012, teriflunomide was approved for the treatment
of RRMS in the USA [25]. Teriflunomide selectively in-
hibits the proliferation of activated T and B lymphocytes.
This effect is achieved already at nanomolar concen-
trations of teriflunomide by blockage of DHODH, an
enzyme involved in de novo pyrimidine synthesis [4].
When used at very high concentrations (>50 μM), teri-
flunomide regulates also other important immune cell
functions [26, 27]. For example, treatment with teriflu-
nomide decreased release of pro-inflammatory cytokines
in human macrophages or peripheral blood lymphocytes
such as IL-6, IL-17, and TNF-α [28–30]. However, phar-
macokinetic studies have revealed that only 1–2 % of the
peripheral teriflunomide might reach the CNS owing to
its low BBB permeability. It is thus conceivable that resi-
dent CNS cells such as microglia may be exposed to low
teriflunomide concentrations around 0.2–0.6 mg/l in vivo,
equivalent to approximately 1–3 μM [10, 11]. In order to
evaluate further mechanisms of action of teriflunomide,
we investigated its effects on microglia in a range of con-
centrations between 0.25 and 5 μM that may be reached
in the CNS by oral administration.
There is only limited knowledge on how teriflunomide
influences the phenotype and function of microglia, the
resident immune cell in the CNS. Microglia characte-
ristically undergo rapid proliferation in response to an
inflammatory insult in the CNS [31]. From our own
experiences and from published reports, we know that
in mixed glial cell cultures, microglia rapidly proliferate
from days 4–5 and that this process is further enhanced
by the addition of growth factors such as GM-CSF
[32, 33]. Interestingly, we observed that microglia up-
regulated DHODH gene expression upon activation.
Consequently, we expected similar inhibitory effects
of teriflunomide on microglial proliferation. We therefore
treated mixed glial cell cultures directly with terifluno-
mide. Teriflunomide treatment significantly lowered the
yield of microglia from GM-CSF-treated mixed glial cell
cultures. A reduced frequency of BrdU+ microglia indi-
cated decreased proliferation (Fig. 3). However, the exact
mechanism how this inhibition is mediated remains to be
clarified. We could exclude cytotoxicity influencing our
results as we did not detect morphological changes as well
Fig. 7 Phagocytic activity of microglia does not change after treatment with teriflunomide. Flow cytometric histograms of unstimulated (a) and
LPS-treated (b) microglia represent the mean fluorescence intensity which displays the amount of incorporated fluorescent latex beads (filled: 4 °C
control; solid line: cells without teriflunomide; dotted line: cells with 5 μM teriflunomide). c, d Data are expressed as the ratio of untreated microglia
in relation to teriflunomide-treated microglia. All data are given as mean ± SD of four independent experiments. For comparison to medium con-
trol, repeated measures ANOVA with Bonferroni’s multiple comparison t tests was used
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as microglial cell death in cells exposed to teriflunomide
(Fig. 2; Additional file 1: Figure S2, Additional file 2:
Figure S3). Since there was an increased expression of
DHODH-mRNA in microglia in response to GM-CSF-
treatment (Fig. 1b), we can speculate that the anti-
proliferative effect of teriflunomide on activated microglia
might be mediated through DHODH inhibition. However,
we do not have direct evidence to support this, a
DHODH-independent mechanism may also act, as we ob-
served proliferation of microglia in mixed glial cell cul-
tures devoid of GM-CSF is similarly affected by
teriflunomide treatment (data not shown), and the con-
centration required to induce this inhibition is much
higher than the concentration that is sufficient to inhibit
T cell proliferation (Additional file 3: Figure S1).
Apart from anti-proliferative effects, reports suggest
that teriflunomide has significant influence on the
inflammatory response of various immune cells. For
example, Cutolo et al. showed that leflunomide, the pro-
drug of teriflunomide, has a concentration-dependent
anti-inflammatory effect on cultured synovial macro-
phages from patients with rheumatoid arthritis [34].
Similar to macrophages, microglia can attain a pro-
inflammatory (M1-like) or an anti-inflammatory (M2-
1ike) phenotype [35]. This led us to ask if teriflunomide
has similar effects on the M1- and M2-like phenotype of
microglia in vitro. Interestingly, at 5 μM of terifluno-
mide, we found a slight but significant enhancement in
the mRNA expression of the anti-inflammatory cytokine
IL-10 in microglia exposed to LPS/IFN-γ. This is in
accordance with the findings of Korn et al. who observed
a similar increase in IL-10 expression in LPS-treated
microglia that were exposed to teriflunomide [36]. On the
other hand, we observed a decreased expression of the co-
stimulatory molecule CD86 on LPS-treated microglia that
were exposed to 5 μM of teriflunomide. However, no sig-
nificant effects were detectable on the mRNA expression
of pro-inflammatory mediators in M1-microglia. Similarly,
the NF-kB pathway, that regulates the expression of pro-
inflammatory cytokines, was unaffected in teriflunomide-
treated microglia. This stands in contrast to studies in a
human T cell line. In this cell line, 5–10 μM of lefluno-
mide were able to block TNF-α-induced NF-kB activation
[21, 37]. This may be due to the lower concentrations of
teriflunomide used in our studies. Furthermore, microglia
seem to be less responsive to teriflunomide as compared
to lymphocytes. Taken together, we believe that low
concentrations of teriflunomide have no major effects on
pro-inflammatory properties of microglia, but higher con-
centration might possibly enhance their anti-inflammatory
properties.
In MS, infiltrating Tcells can mediate CNS damage either
by directly targeting neurons or by triggering an inflam-
matory response in microglia. Furthermore microglia
respond to CNS damage and remove the damaged cells
by phagocytosis. Phagocytosis is one of the main features
of microglial activation. In the past, the importance of
microglia in the clearance of myelin debris and subse-
quent repair processes has been demonstrated [38, 39].
However, we did not observe any enhancing or suppres-
sive effects of teriflunomide on phagocytosis in either
untreated or LPS-activated microglia.
Conclusions
In conclusion, we demonstrate here that by and large,
only the highest concentration of teriflunomide that
microglia may be exposed to in vivo in the CNS has an
effect on proliferation. Furthermore, only stimulation
with the highest concentration of teriflunomide (5 μM)
had a significant effect on mRNA expression of IL-10.
Lower concentrations were not sufficient to modulate
significantly further anti- or pro-inflammatory responses.
Thus, we provide evidence that teriflunomide may have
an effect on microglial proliferation which may be of
importance in the treatment of neuroinflammatory CNS
diseases. Further in vivo studies are required to corrob-
orate this effect.
Additional files
Additional file 1: Figure S2. Teriflunomide does not affect cell viability
of primary microglia. To investigate possible cytotoxic effects of the drug
in the concentrations used in this study, we employed the Alamar blue
cell viability assay (Invitrogen, Darmstadt, Germany), which measures the
oxidation status of the cells without affecting the function of the electron
transport chain. Cells were treated with teriflunomide (stock: 10 mM;
dissolved in dimethyl sulfoxide (DMSO, vehicle); 0.25–5 μM) for (A) 24 h,
(B) 48 h, or (C) 72 h. The medium was completely changed and replaced
with 100 μl cell culture medium supplied with 10 % Alamar blue
solution, and cells were further incubated for 4 h. Fluorescence intensity
of Alamar blue was measured at 570 nm with a microplate reader (Tecan
Sunrise, Crailsheim, Germany). Duplicate measurements were averaged in
four independent experiments. Data are normalized to untreated control
(1st column), presented as mean ± SD and compared to the untreated
control. (TIF 780 kb)
Additional file 2: Figure S3. Teriflunomide does not affect cell death in
cultured primary microglia. Isolated microglia were treated with LPS
(100 ng/ml) and different concentrations of teriflunomide (0.25–5 μM) for
12, 48, or 72 h followed by staining with propidium iodide (PI). (A, B, C)
The percentage of gated PI+ CD11b/c+ cells is presented as mean + SD
(n = 4). (TIF 718 kb)
Additional file 3: Figure S1. Teriflunomide inhibits rodent T cell
proliferation. Single-cell suspensions from spleens of adult Sprague-
Dawley rats (Crl:CD) were prepared in complete IMDM medium. Freshly
isolated rat CD4+ T cells were labeled with 2.5 μM CFSE, stimulated with
plate-bound anti-CD3/CD28 mAb and treated with different concentrations
of teriflunomide (0.25–5 μM) for 65–72 h. Control presents unstimulated
CFSE-labeled cells. (A) Total number of T cells as shown in histograms for
0.5 μM teriflunomide was determined by flow cytometry. (B) For comparison
of proliferation, the number of proliferating T cells (n = 4) repeated measures
ANOVA with Bonferroni’s multiple comparison t test were used. Significant
effects are indicated by asterisks (***p < 0.001). (TIF 162 kb)
Additional file 4: Figure S4. Teriflunomide does not interfere with
astrocytic proliferation or secretion of cytokines and growth factors. (A)
Astrocytes were treated without GM-CSF in mixed glial cell cultures for
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48 h. Cultures were incubated with 10 μM BrdU for the last 16 h, and
dividing astrocytes were then visualized by labeling with a FITC-
conjugated anti-BrdU antibody. For comparison of untreated (0 μM) and
teriflunomide-treated (5 μM) sample (n = 3), a paired t test was used.
(B–E) The columns represent the relative quantity of gene expression of
teriflunomide-treated astrocytes following stimulation with GM-CSF for
12 h (dotted columns) or unstimulated (white columns). The dashed line
represents the basal expression level in untreated, unstimulated astrocytes.
Results are presented as the fold-change of astrocyte-secreted factors
normalized to the expression of the reference gene Hprt1 and were
calculated relative to unstimulated, untreated cells. Data from four
experiments are represented as the mean ± standard deviation. *p < 0.05,
**p < 0.005, ***p < 0.001, compared with the basal expression level (black
column). GM-CSF - granulocyte macrophage-colony stimulating factor;
FGF-2 - fibroblast growth factor 2; RQ - relative quantity. (TIF 930 kb)
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